ja3c02679_si_001.pdf (10.52 MB)
Antigen/Adjuvant-Displaying Enveloped Viral Replica as a Self-Adjuvanting Anti-Breast-Cancer Vaccine Candidate
journal contribution
posted on 2023-06-20, 15:04 authored by Keita Ito, Hiroto Furukawa, Hiroshi Inaba, Shino Ohshima, Yoshie Kametani, Masatoshi Maeki, Manabu Tokeshi, Xuhao Huang, Kazuya Kabayama, Yoshiyuki Manabe, Koichi Fukase, Kazunori MatsuuraWe report a promising cancer vaccine candidate comprising
antigen/adjuvant-displaying
enveloped viral replica as a novel vaccine platform. The artificial
viral capsid, which consists of a self-assembled β-annulus peptide
conjugated with an HER2-derived antigenic CH401 peptide, was enveloped
within a lipid bilayer containing the lipidic adjuvant α-GalCer.
The use of an artificial viral capsid as a scaffold enabled precise
control of its size to ∼100 nm, which is generally considered
to be optimal for delivery to lymph nodes. The encapsulation of the
anionically charged capsid by a cationic lipid bilayer dramatically
improved its stability and converted its surface charge to cationic,
enhancing its uptake by dendritic cells. The developed CH401/α-GalCer-displaying
enveloped viral replica exhibited remarkable antibody-production activity.
This study represents a pioneering example of precise vaccine design
through bottom-up construction and opens new avenues for the development
of effective vaccines.
History
Usage metrics
Categories
Keywords
∼ 100 nmprecise vaccine designopens new avenuesnovel vaccine platformlipid bilayer containingcancer vaccine candidateartificial viral capsidannulus peptide conjugatedanionically charged capsidlipidic adjuvant αsurface chargestudy representsproduction activitypioneering examplelymph nodesgenerally consideredenveloped withineffective vaccinesdeveloped ch401dendritic cellsassembled βadjuvanting anti